GANYMED Pharmaceuticals AG

At GANYMED, we are fully committed to develop new immunotherapeutics to fight cancer, and other life threatening diseases. Dedicated entrepreneurial people are the key to our success and team spirit.

GANYMED fosters an energetic and respectful atmosphere of excellence and team spirit.

Become part of a winning team, and grow professionally and personally in a rewarding environment.

We are currently searching for:

Some forms and documents are available in *-pdf format. You need the Adobe Acrobat Reader® in order to see them. If you do not posses the program you can download it here.

Science

Please forward your application to:

GANYMED Pharmaceuticals AG
Ms. Michaela Lind
Freiligrathstrasse 12

D-55131 Mainz

Phone:
Fax:

E-Mail:

+49 (0) 6131 / 1440 - 100
+49 (0) 6131 / 1440 - 114

m.lind[at]ganymed.ag

[August 2010]

Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety

[April 2010]

ERNST & YOUNG, Deutscher Biotechnologie-Report 2010,

Das "Mainzer Modell": CI3

[Jan 2010]

34. Sendung TV-Magazin „in vivo“: vor Ort im Tumorvakzinationszentrum und bei Ganymed, Mainz (Deutsche Krebshilfe e. V.)

Meet us...

[September 2010]

European Cancer Cluster

Partnering, 15-17 sept. 2010,

(Folketeateret Oslo AS),

Oslo, Norway

[November 2010]

Bio-Europe 2010,

November 15-17, 2010

(International Congress Centre

Munich (ICM))

Ganymed belongs to CI3 - Cluster of

"individualized immunointervention -

ImmunoPolis"

Association for Cancer Immunotherapy

Biotechnologie-Industrie-Organisation Deutschland e.V.

Bio Deutschland e.V.

International Council for the Life Sciences